You are here

  • Home
  • Online First
  • ICS/formoterol maintenance and reliever therapy: how far beyond asthma?

Article Text

Article menu
Download PDFPDF
Editorial
ICS/formoterol maintenance and reliever therapy: how far beyond asthma?

http://dx.doi.org/10.1136/thorax-2022-219979

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All authors contributed to the drafting of this editorial.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests RB has received personal fees from AstraZeneca, Avillion, Cipla and Teva Pharmaceuticals; and is Chair of the New Zealand Asthma & Respiratory Foundation Adolescent and Adult Asthma Guidelines Group. The Medical Research Institute of New Zealand has received research funding from AstraZeneca, Cure Kids (NZ), Genentech and the Health Research Council of New Zealand.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles